Alkermes Plc at JPMorgan Healthcare Conference Transcript
Great. Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Alkermes. We're going to hear a presentation from the management team, and then we're going to go into some Q&A. Because of JPMorgan's involvement with the pending transaction, we're not going to take any Q&A related to the pending deal, and I'm not going to be discussing that.
So with that out of the way, let me turn it over to Alkermes, CEO, Richard Pops.
Good morning. Thank you, Jess. Hi, everybody. I'm actually really excited to get to this presentation today in the new year, tell you about Alkermes in 2026, where we stand today and how the accomplishments in 2025, set us up for what we can now see clearly as our next potential phase of growth.
So with that said, I'm going to make forward-looking statements today, as I always do. And it's described in this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
